Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.

Yost RJ, Cappelletty DM; RECEIPT Study group.

Pharmacotherapy. 2011 Aug;31(8):767-75. doi: 10.1592/phco.31.8.767.

PMID:
21923603
2.

Anidulafungin and its role in candida infections.

Cappelletty DM, Jung R.

Infect Drug Resist. 2009;2:51-60. Epub 2009 Jun 30.

3.

Evaluation of an intracellular pharmacokinetic in vitro infection model as a tool to assess tuberculosis therapy.

Cappelletty DM.

Int J Antimicrob Agents. 2007 Feb;29(2):212-6. Epub 2007 Jan 3.

PMID:
17204402
4.

Assessment of differences in antimicrobial effect determined with two in vitro pharmacodynamic models: impact of surface area to volume ratio.

White RL, Bonapace CR, Friedrich LV, Rybak MJ, Cappelletty DM, Mercier RC, Houlihan HH, Aeschlimann JR, Bosso JA.

Pharmacotherapy. 2003 May;23(5):603-8.

PMID:
12741434
5.

Anaphylactoid reaction to levofloxacin.

Smythe MA, Cappelletty DM.

Pharmacotherapy. 2000 Dec;20(12):1520-3.

PMID:
11130225
6.

Economic impact of aminoglycoside toxicity and its prevention through therapeutic drug monitoring.

Slaughter RL, Cappelletty DM.

Pharmacoeconomics. 1998 Oct;14(4):385-94. Review.

PMID:
10344906
7.

Critical pathways or treatment algorithms in infectious diseases: do they really work?

Cappelletty DM.

Pharmacotherapy. 1999 May;19(5):672-4. No abstract available.

PMID:
10331833
11.
12.

Supplemental Content

Loading ...
Support Center